Massachusetts General Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count).
Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.
Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.
Top-decile sponsor footprint
Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,032 total, page 9 of 41
A Randomized Clinical Trial to Measure Efficacy of Music on Cardiac Surgery Patients
NCT04551469
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
NCT04857684
Laser Treatment of Moderate to Severe Acne Vulgaris
NCT04466527
Remote Monitoring in Progressive Supranuclear Palsy (PSP)
NCT04753320
Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression
NCT04448327
Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe
NCT04565821
Massachusetts General Hospital and Tsuchiura Kyodo General Hospital Coronary Imaging Collaboration
NCT04523194
Supportive Oncology Care At Home RCT
NCT04544046
Reconnecting to Ourselves and Others in Virtual Meetings (ROOM)
NCT06360562
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
NCT04305145
Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness
NCT03814356
Multidisciplinary Intervention In Chronic GVHD
NCT04479995
The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance
NCT04450043
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
NCT04430699
KRDI in Transplant-Eligible MM
NCT04430894
Food Oral Immunotherapy for Peanut Allergy
NCT04222491
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
NCT04361162
Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
NCT04163419
Effects of Auditory Stimulation on Sleep and Memory in Schizophrenia
NCT04783571
Resiliency Training in Adolescents With NF1 and NF2
NCT03873610
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT04039230
Addressing Anxiety in 2-3-Year-Olds: A Pilot Intervention Study
NCT04039243
AZD6738 for Patients With Progressive MDS or CMML
NCT03770429
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
NCT03945721
A Dose-Response Study of the Cognitive and Physiological Effects of tDCS to the DLPFC
NCT04175041
Genome Environment Microbiome and Metabolome in Autism Study
NCT04271774
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
NCT03959891
Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
NCT03674047
A Stress Management and Resiliency Program for Adolescent and Young Adult Survivors
NCT03768336
Calcitriol Monotherapy for X-Linked Hypophosphatemia
NCT03748966
Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement
NCT03716531
Combined Cortical/Subcortical Recording and Stimulation as a Circuit-Oriented Treatment for Obsessive-Compulsive Disorder
NCT03184454
Brain Mechanisms of Video-Guided Acupuncture Imagery Treatment on Chronic Low Back Pain
NCT03765879
A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy
NCT03822312
Multimodal Sexual Dysfunction Intervention In HCT
NCT03803696
Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening
NCT03861975
Screening For BCRL In Targeted Therapy For Breast Cancer
NCT05142800
Sleep Profiles in REM Sleep Behavior Disorder
NCT04886076
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
NCT03623633
Pilot Study for Evaluation of Cryobiopsy and Correlation With Standard Forceps Biopsy
NCT03566160
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
NCT03563248
Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy
NCT03420482
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
NCT03331250
Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation
NCT03281889
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
NCT03362060
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
NCT03285412
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
NCT03149029
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
NCT03279692
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
NCT03286530
A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy
NCT03310918
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 226 |
| Phase 2 | 289 |
| Phase 3 | 58 |
| Phase 4 | 182 |
Therapeutic Areas
What is open in the Massachusetts General Hospital pipeline
336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).
Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).
Top condition: Depression (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.